Tag: Zydus
Cadila Healthcare is now Zydus Lifesciences
Zydus unveils its ‘innovation and care’ centric corporate brand identity
Zydus posts consolidated revenues of Rs. 3655 crores in Q3
The company filed 12 additional ANDAs with the USFDA during the quarter and received 9 new product approvals (including 5 tentative approvals) from the USFDA.
Zydus gets go ahead for phase-2 clinical trial of its novel...
The company will soon begin the Phase II (a) clinical trial of ZYIL1, a novel oral NLRP3 inflammasome inhibitor in patients with Cryopyrin-Associated Periodic Syndrome (CAPS), a rare life-long auto-inflammatory condition in Australia
Zydus seeks DCGI’s EUA for world’s first Plasmid DNA based COVID-19...
The company has presented interim results from Phase III clinical trials in over 28,000 volunteers in a study carried out in more than 50 clinical sites spread across the country and during the peak of second wave of COVID-19.......................
Bayer & Zydus extend their joint venture by 3 years
Bayer Zydus Pharma will continue to operate in therapies including cardiology, diabetes, women’s health, ophthalmology and oncology, with new products in the pipeline.......................
Zydus seeks DCGI approval for the use of Pegylated Interferon alpha-2b...
Promising interim results from Phase III clinical trials with Pegylated Interferon alpha-2b in COVID-19 show higher clinical improvement.........................
Zydus completes Phase-I trials of its anti-malarial compound
Phase I healthy volunteers study demonstrated long half-life and potential for a single-dose cure for malaria. Potent antimalarial activity demonstrated in malaria challenge trial following single-dose oral administration of ZY19489.......................
Zydus’ Desidustat shows efficacy & safety in treating Hypoxia in hospitalized...
Novel mechanism of targeting ‘hypoxia’ through HIF-PH inhibitor was studied for the first time in Hospitalised Covid-19 Patients in Mexico. Study trial indicates that the use of Desidustat for 14 days reduced CRP between baseline and day 14 among hospitalised patients with COVID-19.........................
Zydus Cadila vaccine candidate gets nod for Phase III clinical trials
The candidate has been supported by the National Biopharma Mission (NBM) under the aegis of BIRAC and the Department of Biotechnology, Government of India.......................
Zydus to begin Phase I trials of its inflammation drug, ZYIL1
Phase I trial will study the safety, tolerability, pharmacokinetics and pharmacodynamics of ZYIL1 in healthy human volunteers. Zydus has secured a Strong IP portfolio with multiple patents filed in all major countries.....................